Regorafenib in glioblastoma recurrence: A case report

Cancer Treat Res Commun. 2021:26:100263. doi: 10.1016/j.ctarc.2020.100263. Epub 2020 Dec 10.

Abstract

GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide).

Keywords: Glioblastoma recurrent; Malignant glioma; Regorafenib.

Publication types

  • Case Reports

MeSH terms

  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / therapy*
  • Chemoradiotherapy, Adjuvant / methods
  • Glioblastoma / diagnosis
  • Glioblastoma / therapy*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / therapy*
  • Phenylurea Compounds / therapeutic use*
  • Pyridines / therapeutic use*
  • Temozolomide / therapeutic use
  • Treatment Outcome

Substances

  • Phenylurea Compounds
  • Pyridines
  • regorafenib
  • Temozolomide